Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Coltoff

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Journal of Palliative Medicine|November 11, 2020
An Opportunity for Hospice Referral in Acute Myeloid Leukemia: Prognostic Significance of Hospitalization Status at Time of Second Cycle of Hypomethylating Agents for Patients Ineligible for Intensive Induction ChemotherapyDouglas Tremblay, Rafael Madero-Marroquin, Guido Lancman, et al.
Hematological Oncology|May 16, 2026
Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid LeukemiaGeorgio Medawar, Jean-Sebastien Anoma, Elizabeth Hill, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 7, 2020
Real-World Outcomes of Ruxolitinib Treatment for Polycythemia VeraAlexander Coltoff, Ruben Mesa, Jason Gotlib, et al.
Blood Cancer Journal|October 7, 2025
Outcomes of older patients with TP53-mutated myeloid neoplasmsOmer Jamy, Mobachir El Kettani, Kashish Shah, et al.
British Journal of Haematology|May 22, 2025
Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational statusTalha Badar, James M Foran, Jan Philipp Bewersdorf, et al.
Leukemia & Lymphoma|April 9, 2026
Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)Razan Mohty, Ravi Narra, Alice S Mims, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2022
Graded Cardiac Response Criteria for Patients With Systemic Light Chain AmyloidosisEli Muchtar, Angela Dispenzieri, Brendan Wisniowski, et al.
JAMA Oncology|August 1, 2024
Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain AmyloidosisEli Muchtar, Brendan Wisniowski, Susan Geyer, et al.
Blood Cancer Journal|August 14, 2025
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adultsEthan J Harris, Diren Arda Karaoglu, Madina Sukhanova, et al.
Blood Advances|January 7, 2026
Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopeniasTalha Badar, Ludovica Marando, Eric Latorre-Crespo, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Journal of Palliative Medicine|November 11, 2020
An Opportunity for Hospice Referral in Acute Myeloid Leukemia: Prognostic Significance of Hospitalization Status at Time of Second Cycle of Hypomethylating Agents for Patients Ineligible for Intensive Induction ChemotherapyDouglas Tremblay, Rafael Madero-Marroquin, Guido Lancman, et al.
Hematological Oncology|May 16, 2026
Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid LeukemiaGeorgio Medawar, Jean-Sebastien Anoma, Elizabeth Hill, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 7, 2020
Real-World Outcomes of Ruxolitinib Treatment for Polycythemia VeraAlexander Coltoff, Ruben Mesa, Jason Gotlib, et al.
Blood Cancer Journal|October 7, 2025
Outcomes of older patients with TP53-mutated myeloid neoplasmsOmer Jamy, Mobachir El Kettani, Kashish Shah, et al.
British Journal of Haematology|May 22, 2025
Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational statusTalha Badar, James M Foran, Jan Philipp Bewersdorf, et al.
Leukemia & Lymphoma|April 9, 2026
Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)Razan Mohty, Ravi Narra, Alice S Mims, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2022
Graded Cardiac Response Criteria for Patients With Systemic Light Chain AmyloidosisEli Muchtar, Angela Dispenzieri, Brendan Wisniowski, et al.
JAMA Oncology|August 1, 2024
Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain AmyloidosisEli Muchtar, Brendan Wisniowski, Susan Geyer, et al.
Blood Cancer Journal|August 14, 2025
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adultsEthan J Harris, Diren Arda Karaoglu, Madina Sukhanova, et al.
Blood Advances|January 7, 2026
Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopeniasTalha Badar, Ludovica Marando, Eric Latorre-Crespo, et al.
Pageof 3